{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:21:53Z","timestamp":1792797713148,"version":"4.5.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) based on the ZUMA-2 cohort 1 (ClinicalTrials.gov identifier: NCT02601313) study in which brexu-cel demonstrated a 93% objective response rate (ORR) and 67% complete response (CR) rate in patients with R\/R MCL and previous BTKi therapy (N = 60). Here, we report the primary results of ZUMA-2 cohort 3 (brexu-cel in patients with BTKi-naive R\/R MCL). Adults received brexu-cel at 2 \u00d7 106 anti-CD19 CAR T cells per kilogram. The primary end point was ORR assessed by independent radiology review committee (IRRC). As of 26 November 2023, 95 patients were enrolled, and 86 received brexu-cel; median follow-up was 15.5 months. The primary end point was met, with a 91% ORR (95% confidence interval [CI], 82.5-95.9; P&amp;lt; .0001; N = 86) and a CR rate of 73% (95% CI, 62.6-82.2). Estimated 12-month progression-free survival (PFS), duration of response, and overall survival (OS) rates were 75%, 80%, and 90%, respectively. Among 95 enrolled patients, the ORR was 82%, the CR rate was 66%, and the 12-month PFS and OS rates (95% CI) were 73% (62.1-80.8) and 85% (75.6-90.7), respectively. Most patients (88%) experienced treatment-related grade \u22653 adverse events, including 4 treatment-related grade 5 events. Consistent with cohort 1, brexu-cel demonstrated a high ORR and similar safety profile. These results support the continued use of brexu-cel in patients with R\/R MCL, and consideration in some patients without previous BTKi therapy who have high-risk disease. This trial was registered at clinicaltrials.gov as #NCT04880434.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029734","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:49:08Z","timestamp":1761767348000},"page":"1302-1314","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Brexucabtagene autoleucel for BTKi-naive relapsed\/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3"],"prefix":"10.1182","volume":"147","author":[{"given":"Tom","family":"van Meerten","sequence":"first","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Amsterdam University Medical Center, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"4Department of Hematology\/Oncology, Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Mutsaers","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro Mart\u00edn","family":"Garc\u00eda-Sancho","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Salamanca University Hospital of Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, University of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-6522","authenticated-orcid":false,"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"7John Theurer Cancer Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gin\u00e9","sequence":"additional","affiliation":[{"name":"8Hospital Cl\u00ednic of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"9Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"11Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"12Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Galal","sequence":"additional","affiliation":[{"name":"13Carol G. Simon Cancer Center, Morristown, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-476X","authenticated-orcid":false,"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[{"name":"14Department of Clinical Hematology, H\u00e9matologie Clinique, Centre Hospitalier Universitaire Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-2833","authenticated-orcid":false,"given":"Robin","family":"Sanderson","sequence":"additional","affiliation":[{"name":"15Department of Haematology, King's College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[{"name":"16Department of Clinical Hematology and Cellular Therapy, Service d'H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"17Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Centre Hospitalier Universitaire Rennes, Universit\u00e9 Rennes, INSERM, \u00c9tablissement Fran\u00e7ais du Sang, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zheng","sequence":"additional","affiliation":[{"name":"19Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangshu","family":"Zhang","sequence":"additional","affiliation":[{"name":"19Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kanska","sequence":"additional","affiliation":[{"name":"19Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8883-0727","authenticated-orcid":false,"given":"Rhine R.","family":"Shen","sequence":"additional","affiliation":[{"name":"19Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Damico Khalid","sequence":"additional","affiliation":[{"name":"19Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Kloos","sequence":"additional","affiliation":[{"name":"19Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"20Department of Medicine III, Ludwig Maximilian University Hospital of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"21Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026031911220890300_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-023-01520-7","article-title":"Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium","volume":"16","author":"Vose","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2026031911220890300_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"key":"2026031911220890300_bib3","doi-asserted-by":"crossref","first-page":"107385","DOI":"10.1016\/j.leukres.2023.107385","article-title":"The shifting therapeutic paradigm for relapsed\/refractory mantle cell lymphoma","volume":"134","author":"Arun Kumar","year":"2023","journal-title":"Leuk Res"},{"issue":"3","key":"2026031911220890300_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"key":"2026031911220890300_bib5","unstructured":"Imbruvica (ibrutinib)\n          . Summary of product characteristics. Janssen-Cilag SpA. Accessed 1 January 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imbruvica-epar-product-information_en.pdf."},{"key":"2026031911220890300_bib6","unstructured":"Brukinsa (zanubrutinib)\n          . Prescribing information. BeiGene, Ltd. Accessed 1 January 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213217s011lbl.pdf."},{"key":"2026031911220890300_bib7","unstructured":"Calquence (acalabrutinib)\n          . Prescribing information. AstraZeneca. Accessed 1 February 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210259s011lbl.pdf."},{"key":"2026031911220890300_bib8","unstructured":"Calquence (acalabrutinib)\n          . Summary of product characteristics. AstraZeneca AB. Accessed 1 February 2025. www.ema.europa.eu\/en\/documents\/product-information\/calquence-epar-product-information_en.pdf."},{"key":"2026031911220890300_bib9","doi-asserted-by":"crossref","first-page":"101221","DOI":"10.1016\/j.blre.2024.101221","article-title":"Dismantling relapsed\/refractory mantle cell lymphoma","volume":"67","author":"Ryan","year":"2024","journal-title":"Blood Rev"},{"issue":"14","key":"2026031911220890300_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031911220890300_bib11","unstructured":"Tecartus (brexucabtagene autoleucel)\n          . Prescribing information. Kite Pharma, Inc. Accessed 11 January 2026. https:\/\/www.fda.gov\/media\/140409\/download?attachment."},{"key":"2026031911220890300_bib12","unstructured":"Tecartus (brexucabtagene autoleucel)\n          . Summary of product characteristics. Kite Pharma EU B.V.. Accessed 11 January 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecartus-epar-product-information_en.pdf."},{"issue":"3","key":"2026031911220890300_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026031911220890300_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2023-179269","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis of high-risk characteristics [abstract]","volume":"142","author":"Kambhampati","year":"2023","journal-title":"Blood"},{"key":"2026031911220890300_bib15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/01.HS9.0000848672.43673.8a","article-title":"P1454: real-world outcomes of brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed or refractory (R\/R) mantle cell lymphoma (MCL) in the United States (US)","volume":"6","author":"Locke","year":"2022","journal-title":"HemaSphere"},{"issue":"6","key":"2026031911220890300_bib16","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"},{"issue":"12","key":"2026031911220890300_bib17","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"issue":"27","key":"2026031911220890300_bib18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026031911220890300_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026031911220890300_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026031911220890300_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026031911220890300_bib22","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2026031911220890300_bib23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2026031911220890300_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"14","key":"2026031911220890300_bib25","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10121","key":"2026031911220890300_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"suppl","key":"2026031911220890300_bib33","article-title":"ZUMA-2: phase 2 multicenter study evaluating efficacy of KTE-C19 in patients with relapsed\/refractory mantle cell lymphoma [abstract]","volume":"36","author":"Wang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026031911220890300_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"6","key":"2026031911220890300_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/12\/1302\/2509394\/blood_bld-2025-029734-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/12\/1302\/2509394\/blood_bld-2025-029734-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:22:14Z","timestamp":1773933734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/12\/1302\/547971\/Brexucabtagene-autoleucel-for-BTKi-naive-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029734","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,19]]},"published":{"date-parts":[[2026,3,19]]}}}